|Mr. John F. Thero||Pres, CEO & Director||1.15M||N/A||1961|
|Mr. Michael W. Kalb||CFO, Sr. VP & Assistant Sec.||597.88k||N/A||1971|
|Dr. Steven B. Ketchum||Pres of R&D, Sr. VP and Chief Scientific Officer||651.58k||N/A||1965|
|Mr. Joseph T. Kennedy||Exec. VP, Gen. Counsel & Strategic Initiatives||778.68k||N/A||1968|
|Ms. Elisabeth Schwartz||Sr. Director of Investor Relations||N/A||N/A||N/A|
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has a collaboration with Mochida Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Biologix FZCo, and HLS Therapeutics, Inc. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Amarin Corporation plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.